Edwards Lifesciences trails Dow despite Strong Buy consensus
Edwards shares gained 11.4 per cent over 12 months, behind the Dow’s 17.1 per cent rise, while analysts maintained a bullish outlook.
Edwards Lifesciences shares have underperformed the Dow Jones Industrial Average over the past year, despite continued support from Wall Street analysts.
The stock gained 11.4 per cent over 52 weeks, compared with a 17.1 per cent rise for the Dow. Edwards was also 6.6 per cent below its reported 52-week high of US$96.29 and had traded above both its 50-day and 200-day moving averages.
The cardiovascular medical-device company reported second-quarter 2026 net sales of US$1.7 billion, up 13.6 per cent from a year earlier. Adjusted earnings per share came in at US$0.78.
Edwards also raised its 2026 sales-growth guidance to between 10 per cent and 11 per cent, from a previous range of 9 per cent to 11 per cent.
According to the Yahoo Finance and Barchart report, the consensus rating among 30 analysts is “Strong Buy”. The mean price target is US$102.03, which the source says implies 13.5 per cent upside from current levels.
The analyst rating and price target represent a consensus view and are subject to changes in market conditions. Boston Scientific shares fell 55.5 per cent over the same period, leaving Edwards as the stronger performer between the two companies.
